Cargando…

Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy

BACKGROUND: Breast cancer patients with positive sentinel lymph node biopsy (SLNB) may be spared axillary lymph node dissection (ALND) in favour of irradiation. The aim of the study was to estimate local control probability in the axilla (axLCP). MATERIALS AND METHODS: We identified 1832 invasive br...

Descripción completa

Detalles Bibliográficos
Autores principales: Falco, Michał, Masojć, Bartłomiej, Kram, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575356/
https://www.ncbi.nlm.nih.gov/pubmed/34760313
http://dx.doi.org/10.5603/RPOR.a2021.0101
_version_ 1784595664378789888
author Falco, Michał
Masojć, Bartłomiej
Kram, Andrzej
author_facet Falco, Michał
Masojć, Bartłomiej
Kram, Andrzej
author_sort Falco, Michał
collection PubMed
description BACKGROUND: Breast cancer patients with positive sentinel lymph node biopsy (SLNB) may be spared axillary lymph node dissection (ALND) in favour of irradiation. The aim of the study was to estimate local control probability in the axilla (axLCP). MATERIALS AND METHODS: We identified 1832 invasive breast cancer patients who had undergone SLNB at our centre. We measured maximal metastasis diameter (SLDmax) in the sentinel lymph nodes and lymph node metastasis volume (VALN) from ALND in 246 patients with one or two positive SLNs. We calculated axLCP after irradiation and systemic treatment for different molecular types. RESULTS: VALN values are higher for high grade tumours and larger metastases in SLNs (> 5 mm). It is smaller in luminal A tumours. axLCP is high, nearly 100%, in all molecular types in radiation sensitive tumours (SF2 Gy = 0.45), except luminal B. Expected axLCP is relatively low (67%) in luminal B radiation sensitive tumours with no chemotherapy and nearly 100% with chemotherapy. CONCLUSION: VALN values differ among molecular tumour types. They depend on SLNDmax and tumour grade. New prognostic factors are needed for selected luminal B breast cancer patients (i.e. high grade tumours, large metastases in SLNs) after positive SLNB intended to be spared ALND and chemotherapy.
format Online
Article
Text
id pubmed-8575356
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-85753562021-11-09 Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy Falco, Michał Masojć, Bartłomiej Kram, Andrzej Rep Pract Oncol Radiother Research Paper BACKGROUND: Breast cancer patients with positive sentinel lymph node biopsy (SLNB) may be spared axillary lymph node dissection (ALND) in favour of irradiation. The aim of the study was to estimate local control probability in the axilla (axLCP). MATERIALS AND METHODS: We identified 1832 invasive breast cancer patients who had undergone SLNB at our centre. We measured maximal metastasis diameter (SLDmax) in the sentinel lymph nodes and lymph node metastasis volume (VALN) from ALND in 246 patients with one or two positive SLNs. We calculated axLCP after irradiation and systemic treatment for different molecular types. RESULTS: VALN values are higher for high grade tumours and larger metastases in SLNs (> 5 mm). It is smaller in luminal A tumours. axLCP is high, nearly 100%, in all molecular types in radiation sensitive tumours (SF2 Gy = 0.45), except luminal B. Expected axLCP is relatively low (67%) in luminal B radiation sensitive tumours with no chemotherapy and nearly 100% with chemotherapy. CONCLUSION: VALN values differ among molecular tumour types. They depend on SLNDmax and tumour grade. New prognostic factors are needed for selected luminal B breast cancer patients (i.e. high grade tumours, large metastases in SLNs) after positive SLNB intended to be spared ALND and chemotherapy. Via Medica 2021-09-30 /pmc/articles/PMC8575356/ /pubmed/34760313 http://dx.doi.org/10.5603/RPOR.a2021.0101 Text en © 2021 Greater Poland Cancer Centre https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
spellingShingle Research Paper
Falco, Michał
Masojć, Bartłomiej
Kram, Andrzej
Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
title Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
title_full Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
title_fullStr Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
title_full_unstemmed Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
title_short Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
title_sort molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575356/
https://www.ncbi.nlm.nih.gov/pubmed/34760313
http://dx.doi.org/10.5603/RPOR.a2021.0101
work_keys_str_mv AT falcomichał moleculartypeandmaximalmetastasisdiameterinfluenceriskofaxillaryrecurrenceinbreastcancerpatientsafterpositivesentinellymphnodebiopsy
AT masojcbartłomiej moleculartypeandmaximalmetastasisdiameterinfluenceriskofaxillaryrecurrenceinbreastcancerpatientsafterpositivesentinellymphnodebiopsy
AT kramandrzej moleculartypeandmaximalmetastasisdiameterinfluenceriskofaxillaryrecurrenceinbreastcancerpatientsafterpositivesentinellymphnodebiopsy